Sleep, Vigilance, and Seizures
How drugs that disrupt sleep can increase seizure risk: a neuroscience perspective
Seizures are usually framed as a problem of epileptic hyperexcitable circuits. However, the brain’s excitability is continuously shaped by how long it has been awake, where it is in the sleep cycle, and how well its sleep architecture has been preserved. A significant number of widely-used drugs alter that architecture, and the consequences can include seizures in people with no epilepsy diagnosis.
Sleep Duration and Cortical Excitability
Cortical excitability (the profile expected to lower seizure threshold) follows the sleep-wake cycle in a measurable way.
At the cellular level, sleep deprivation reduces GABAergic inhibition and shifts the excitation-inhibition balance toward runaway firing.
The clinical threshold has been quantified in humans with implanted electrodes: each additional 1.7 hours of sleep reduced the probability of a seizure in the following 48 hours by approximately 27%. Sleep quantity has a direct, graded relationship with seizure likelihood. Sleep deprivation also activates epileptiform discharges on EEG in people without known epilepsy.
Sleep Stages and Seizure Timing
Seizure risk varies substantially across sleep stages. NREM sleep — particularly stages N1 and N2 — and the transitions between sleep and wakefulness are consistently identified as high-risk periods. These states involve large-amplitude synchronized thalamocortical oscillations; these neural dynamics overlap with the early synchronization pattern of a generalizing seizure [Nobili et al., 2022; Xu et al., 2020].
REM sleep exerts the opposite effect. The desynchronized, cholinergically-driven REM resists the kind of broad synchrony that most seizures require. Reviews consistently identify REM as the stage with lowest seizure incidence, and REM deprivation — for example in obstructive sleep apnea — is associated with worsened seizure control [Goyal et al., 2023].
Circadian timing adds another layer. Seizure probability clusters at specific times of day, and the circadian clock modulates excitability through molecular pathways that overlap with sleep-stage regulation [Xu et al., 2020]. Any drug that shifts circadian phase or fragments the sleep-wake cycle is operating in this same space.
The practical upshot: disrupting normal sleep architecture — fragmenting NREM, suppressing REM, or flattening the sleep cycle — moves the brain’s excitability state in a direction that increases seizure susceptibility.
Drugs That Reshape Sleep Architecture
A large number of commonly prescribed and used substances alter sleep architecture as a primary pharmacological effect. For several drug classes, this alteration is directly relevant to seizure risk.
Alcohol
Alcohol’s effects on sleep are well characterized. Acute intake shortens sleep latency and suppresses REM in the first part of the night. Chronic use reduces slow-wave N3 sleep, fragments sleep continuity, and produces polysomnographic abnormalities that persist into abstinence [He et al., 2019]. A 2023 meta-analysis of polysomnographic data in alcohol use disorder found significantly longer sleep onset latency, lower sleep efficiency, reduced stage 2 and slow-wave sleep, and elevated REM density [Yang et al., 2023].
During withdrawal, these changes intensify. Animal models show acute withdrawal produces reduced REM, increased wakefulness, fragmentation, and spindle frequency changes [Brandner et al., 2022]. Simultaneously, the brain’s compensatory upregulation of excitatory glutamatergic tone — the adaptation that maintained function during chronic alcohol exposure — is now unopposed. The combination of sleep fragmentation, REM instability, and GABAergic disinhibition creates the neurophysiological substrate for alcohol withdrawal seizures. Sleep disruption and hyperexcitability are part of the same process.
Benzodiazepines and GABAergic Sedatives
Benzodiazepines and Z-drugs reduce N3 sleep and suppress slow delta oscillations while increasing N2 spindle activity. Benzodiazepine use is associated with reduced sleep depth and altered sleep architecture, with abrupt withdrawal producing rebound insomnia and, at the severe end, convulsions [Jupe et al., 2024]. Polysomnographic studies in older adults with chronic insomnia found that chronic benzodiazepine receptor agonist use was dose-dependently associated with lower N3, higher N1, and disrupted slow oscillation-spindle coupling [Barbaux et al., 2025].
The withdrawal seizure risk from benzodiazepines is well established. The mechanism follows the same pattern as alcohol: the brain adapts to chronic GABAergic enhancement by downregulating its own inhibitory tone, and abrupt removal exposes that adaptation as rebound hyperexcitability.
An additional complication arises in alcohol withdrawal treatment. Benzodiazepines and clomethiazole, commonly used to bridge the withdrawal period, suppress REM and delta sleep during the treatment phase and can produce their own rebound dysregulation on cessation [Gann et al., 2004]. Managing one withdrawal creates the conditions for another.
Antidepressants
SSRIs, SNRIs, TCAs, and MAOIs are potent REM suppressors as a class [Takagi, 2023]. SSRIs and SNRIs in particular are associated with disrupted sleep architecture, impaired slow-wave sleep, and increased periodic limb movements — a further source of sleep fragmentation [Marey et al., 2024; Ujma & Bódizs, 2024].
Whether antidepressant-induced REM disruption independently raises seizure risk — beyond any direct seizurogenic effects of specific molecules like bupropion or high-dose TCAs — has not been cleanly resolved. The mechanistic pathway is coherent, but the clinical evidence separating sleep-mediated from direct effects remains limited. Abrupt antidepressant discontinuation produces REM rebound and sleep disruption that, in the context of the neurophysiology reviewed above, carries real biological significance for excitability.
Stimulants
Amphetamines, cocaine, and methylphenidate extend wakefulness, increase sleep latency, and raise REM latency [Schierenbeck et al., 2008]. Chronic stimulant use produces cumulative sleep restriction alongside architectural distortion. On the basis of the excitability data reviewed above, this profile is expected to reduce seizure threshold over time. Whether the sleep-mediated pathway contributes meaningfully to seizure events in stimulant users — as distinct from the drugs’ direct neurochemical actions — remains an open question, but the physiological case is grounded.
Opioids
Opioids reduce slow-wave sleep, suppress REM, and worsen sleep-disordered breathing [Bohra et al., 2014]. Long-term opioid users accumulate significant architectural sleep debt even when total time in bed is adequate. The seizure risk from opioids involves multiple pathways; the sleep disruption component is a distinct contributor that tends to be overlooked in clinical assessments.
Clinical Considerations
For prescribers: When initiating or discontinuing any drug that alters sleep architecture — alcohol, benzodiazepines, GABAergic sedatives, most antidepressants, stimulants, opioids — consider whether the resulting change in sleep quality shifts seizure threshold in a patient who may have limited reserve. The risk is highest with abrupt discontinuation of GABAergic agents, and is compounded by concurrent sleep restriction from any cause (shift work, illness, pain, other medications).
For patients: The reason clinicians recommend tapering sedatives, alcohol, or sleep-affecting drugs rather than stopping abruptly is grounded in this physiology. The brain that has adapted to a GABAergic drug needs time to re-establish its own inhibitory tone. Removing the drug without that transition creates a window of genuine cortical hyperexcitability that can produce seizures in someone with no prior seizure history.
For clinical thinking more broadly: A drug’s effect on sleep architecture belongs in the safety profile alongside its direct seizure risk. The two are related but distinct mechanisms, and the sleep-mediated one is regularly omitted from clinical reasoning.
Summary
Sleep is a pharmacologically active brain state. The sleep-wake cycle continuously regulates cortical excitability, with NREM transitions elevating and REM suppressing seizure susceptibility. A 2025 meta-analysis now provides robust population-level evidence that sleep deprivation measurably reduces cortical inhibition. Many drugs in routine use — across addiction medicine, psychiatry, and pain management — alter the sleep architecture that maintains this inhibitory tone. For alcohol and GABAergic sedatives, the link from sleep disruption to withdrawal seizure is mechanistically direct. For antidepressants, stimulants, and opioids, the sleep-architecture pathway adds a layer of risk that warrants consideration alongside the drugs’ direct pharmacological effects.
References
1. Zhang Y, et al. Cortical excitability on sleep deprivation measured by transcranial magnetic stimulation: A systematic review and meta-analysis. Brain Research Bulletin. 2025;221:111190. DOI: 10.1016/j.brainresbull.2025.111190
2. Salehinejad MA, et al. Sleep-dependent upscaled excitability, saturated neuroplasticity, and modulated cognition in the human brain. eLife. 2022;11. DOI: 10.7554/eLife.69308
3. Chia C-H, et al. Cortical excitability signatures for the degree of sleepiness in human. eLife. 2021;10. DOI: 10.7554/ELIFE.65099
4. Dell KL, et al. Seizure likelihood varies with day-to-day variations in sleep duration in patients with refractory focal epilepsy. medRxiv. 2021. DOI: 10.1101/2021.05.03.21256436
5. Nobili L, et al. Sleep and epilepsy: A snapshot of knowledge and future research lines. Journal of Sleep Research. 2022;31(4). DOI: 10.1111/jsr.13622
6. Xu C, et al. Decoding Circadian Rhythm and Epileptic Activities: Clues From Animal Studies. Frontiers in Neurology. 2020;11:751. DOI: 10.3389/fneur.2020.00751
7. Yang P, Weng J, Huang X. Sleep features in alcohol use disorder: A systematic review and meta-analysis of polysomnographic findings. European Journal of Psychiatry. 2023. DOI: 10.1016/j.ejpsy.2023.100231
8. He S, Hasler BP, Chakravorty S. Alcohol and sleep-related problems. Current Opinion in Psychology. 2019;30:117–122. DOI: 10.1016/j.copsyc.2019.03.007
9. Brandner AJ, et al. Effects of Alcohol Withdrawal on Sleep Macroarchitecture and Microarchitecture. Frontiers in Neuroscience. 2022;16. DOI: 10.3389/fnins.2022.838486
10. Jupe T, Provi K, Giannopoulos I. Sleep architecture disturbance due to the use of benzodiazepines. European Psychiatry. 2024;67(S1):S775. DOI: 10.1192/j.eurpsy.2024.1614
11. Barbaux L, et al. Effect of chronic benzodiazepine and benzodiazepine receptor agonist use on sleep architecture and brain oscillations in older adults with chronic insomnia. Sleep. 2025. DOI: 10.1093/sleep/zsaf168
12. Gann H, et al. Polysomnography during withdrawal with clomethiazole or placebo in alcohol dependent patients. Pharmacopsychiatry. 2004;37(5):228–235.
13. Takagi Y. Antidepressants and sleep. In: Sleep Medicine. 2023:340–346. DOI: 10.1016/b978-0-12-822963-7.00073-6
14. Marey H, Chai A, Bikov A. Periodic limb movements in sleep in patients using antidepressants. Sleep Medicine Reviews. 2024. DOI: 10.1016/j.smrv.2024.102011
15. Ujma PP, Bódizs R. Sleep alterations as a function of 88 health indicators. BMC Medicine. 2024;22(1). DOI: 10.1186/s12916-024-03358-3
16. Goyal A, et al. Obstructive sleep apnea and epilepsy: understanding the pathophysiology of the comorbidity. Int J Physiol Pathophysiol Pharmacol. 2023.
17. Huber R, et al. Human Cortical Excitability Increases with Time Awake. Cerebral Cortex. 2013;23(2). DOI: 10.1093/cercor/bhs014
18. Fountain NB, Kim JS, Lee SI. Sleep Deprivation Activates Epileptiform Discharges Independent of the Activating Effects of Sleep. J Clin Neurophysiology. 1998;15(1):69–75.
19. Schierenbeck T, et al. Effect of illicit recreational drugs upon sleep. Sleep Medicine Reviews. 2008;12(5):381–389.
20. Bohra MH, et al. Weighing the balance: how analgesics used in chronic pain influence sleep? British Journal of Pain. 2014;8(3):107–118.